证券代码：300677 证券简称：英科医疗 英科医疗科技股份有限公司 投资者关系活动记录表 编号：2021-001 | --- | --- | --- | --- | --- | --- | --- | |------------------|---------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|-------------|--------------| | | | | | | | | | 投资者关系活动类 | ■特定对象调研 | | □分析师会议 | | | | | 别 | □媒体采访 □业绩说明会 | | | | | | | | □新闻发布会 □路演活动 | | | | | | | | ■现场参观 □一对一沟通 | | | | | | | | □其他 | | | | | | | | -机构投资者： | | | | | | | | 东北证券 唐 凯； | 东 ...

证券代码：300677 证券简称：英科医疗 英科医疗科技股份有限公司 投资者关系活动记录表 编号：2021-003 | --- | --- | --- | --- | --- | --- | --- | |------------------|------------------------------------------------------------------------------|--------------------------------------------|--------|----------|--------------|-------| | | | | | | | | | | ■特定对象调研 | □分析师会议 | | | | | | | | □媒体采访 □业绩说明会 | | | | | | 投资者关系活动类 | □新闻发布会 □路演活动 | | | | | | | 别 | □其他 | ■现场参观 □一对一沟通 | | | | | | | -机构投资者： | | | | | | | | 景林资产 蒋 | 彤； 大成基金 邹 建； 前海开源 | | | 黄智然； | | | | ...

Company Overview - The chairman of Yingke Medical has over 30 years of industry experience and established the company in 2009, focusing on R&D and technology enhancement [3][4] - The company aims to become a leading high-tech enterprise in medical consumables and devices, leveraging its global marketing channels in over 120 countries [3][4] Production Capacity - As of June 2021, the annual production capacity reached 51 billion pieces, with 27 billion being nitrile gloves and 24 billion PVC gloves [4] - The company has expanded its production capacity significantly from 19 billion pieces at the end of 2019 to 36 billion pieces by the end of 2020 [4] Industry Landscape - The number of global glove manufacturers increased from 120-150 before the pandemic to over 300 during the pandemic, but many smaller firms are expected to exit the market as prices stabilize [5] - Post-pandemic, it is anticipated that only 10-30 manufacturers will remain, with leading companies covering over 80% of the global market [5] Competitive Advantages - Yingke Medical maintains competitive production efficiency and a larger talent pool compared to Malaysian competitors, which face challenges such as high worker infection rates during the pandemic [5][6] - The company benefits from lower raw material costs and a favorable tax rate of 15% compared to Malaysia's 24% [6] Marketing Strategy - The company has established marketing centers in the US, Canada, Germany, Hong Kong, and Singapore, with plans to expand further in the next 2-3 years [6] - It has served over 10,000 clients across more than 120 countries, with a healthy customer composition that includes both long-term and new clients [6] Domestic Market Insights - Prior to the pandemic, the average annual usage of medical gloves in China was only 6 pieces per person, which saw a significant increase during the pandemic [6] - Domestic sales accounted for over 20% of total sales, with some domestic products being exported [6]

证券代码：300677 证券简称：英科医疗 英科医疗科技股份有限公司 投资者关系活动记录表 编号：2021-005 | --- | --- | --- | --- | --- | --- | |------------------|----------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|-------|------------------|-------| | | | | | | | | | ■特定对象调研 | □分析师会议 | | | | | 投资者关系活动类 | □媒体采访 □业绩说明会 | | | | | | 别 | □新闻发布会 □路演活动 | | | | | | | ■现场参观 □一对一沟通 | | | | | | | □其他 | | | | | | | | ...

证券代码：300677 证券简称：英科医疗 公告编号：2022-102 英科医疗科技股份有限公司 关于参加山东辖区上市公司 2022 年度 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，英科医疗科技股份有限公司 （以下简称"公司"）将参加由山东证监局联合山东上市公司协会等 单位举办的"山东辖区上市公司 2022 年度投资者网上集体接待日活 动"，现将有关事项公告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的互 联网平台举行，投资者可登录全景网"投资者关系互动平台" （http://ir.p5w.net）参与公司本次投资者集体接待日活动，活动时间为 2022 年 11 月 16 日（星期三）14:00-16:00。 届时公司董事会秘书李斌先生、财务总监冯杰女士，将通过网络 在线交流形式与投资者就公司治理及社会责任（ESG）、经营状况、发 展战略、风险防控、投资者保护、2022 年第三季度报告等投资者关注 的问题进行沟通。欢迎广大投资者积极参与！ 特此公告。 英科医疗科技股份有限公司 董 事 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥1,471,788,445, a decrease of 50.48% compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2022 was ¥236,207,795, down 77.79% year-on-year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥182,176,188, a decline of 82.83% compared to the previous year[7]. - The basic earnings per share for Q3 2022 was ¥0.36, representing a decrease of 77.36% year-on-year[7]. - The company reported a significant decrease in operating income for the first nine months of 2022, totaling ¥5,212,259,481, down 61.81% year-on-year[12]. - Total operating revenue for the current period is $5.21 billion, a decrease of 61.7% from $13.65 billion in the previous period[36]. - Net profit for the current period is $632.88 million, a decline of 90.9% compared to $6.97 billion in the previous period[38]. - Total profit for the current period is $839.66 million, a decrease of 89.6% from $8.09 billion in the previous period[38]. Assets and Liabilities - Total assets at the end of Q3 2022 were ¥20,297,045,673, a decrease of 1.59% from the end of the previous year[7]. - The company’s total equity attributable to shareholders at the end of Q3 2022 was ¥15,912,191,683, a slight increase of 0.26% from the end of the previous year[7]. - The company's total current assets decreased to RMB 9.29 billion from RMB 10.76 billion, a decline of 13.7%[30]. - The company's total liabilities decreased to RMB 4.14 billion from RMB 4.50 billion, a reduction of 8.1%[32]. - The company's total equity increased to RMB 16.16 billion from RMB 16.12 billion, reflecting a growth of 0.2%[32]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥1,290,552,992, down 84.42% compared to the same period last year[7]. - Net cash flow from operating activities decreased by 84.42% to 1,290,552,992 from 8,282,856,582, mainly due to a decrease in cash received from sales[15]. - Cash flow from operating activities generated $1.29 billion, a decrease of 84.4% from $8.28 billion in the previous period[42]. - Cash inflows from financing activities totaled 1,020,593,466.00, compared to 575,045,674.00 in the previous period[45]. - Cash outflows from financing activities amounted to 1,457,247,972.00, an increase from 1,126,800,743.00 in the previous period[45]. - The net increase in cash and cash equivalents was 1,343,002,052.00, compared to 541,512,985.00 in the previous period[45]. Investments and Expenses - The company experienced a 1634.60% increase in investment income for the first nine months, amounting to ¥29,933,159[12]. - The company reported a 225.84% increase in fair value changes in investment income, totaling ¥61,711,328 for the first nine months[12]. - Operating expenses rose by 68.51% to 24,081,371 from 14,290,970, mainly due to increased donation expenses during the reporting period[15]. - Research and development expenses for the current period are $198.42 million, a reduction of 25% from $264.56 million in the previous period[36]. - Sales expenses decreased to $175.73 million, down 33.5% from $264.47 million in the previous period[36]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 86,877, with the top ten shareholders holding 35.06% of shares[16]. - Liu Fangyi, a major shareholder, holds 35.06% of shares, totaling 231,221,607[16]. - The company has allocated between RMB 250 million and RMB 500 million for share repurchase to implement employee stock ownership plans and/or equity incentives[26]. - The maximum repurchase price was set at RMB 34.38 per share, with the highest transaction price recorded at RMB 25.20 per share[26]. - The company has repurchased a total of 11,677,725 shares, accounting for 1.7706% of the total share capital, with a total transaction amount of approximately RMB 269 million[26]. Project Updates - The company terminated the high-end medical glove project with an annual production capacity of 40 billion units, as well as a cogeneration project in the Changlingqi New Port area[25]. - The company completed the registration of the restricted stock incentive plan on September 15, 2022, with 5,886,000 shares added to the restricted stock[24]. Miscellaneous - The impact of exchange rate changes on cash and cash equivalents was a significant decrease of 2,203.84% to 389,631,704 from -18,520,047[15]. - The company's third-quarter report was not audited[46].

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[20]. - The net profit attributable to shareholders was RMB 300 million, up 10% compared to the same period last year[20]. - The company's operating revenue for the reporting period was ¥3,740,471,036, a decrease of 64.96% compared to the same period last year, which was ¥10,674,384,097[29]. - Net profit attributable to shareholders was ¥402,339,243, down 93.16% from ¥5,878,816,124 in the previous year[29]. - The net cash flow from operating activities was ¥768,756,985, reflecting an 88.50% decline from ¥6,682,399,469 in the same period last year[29]. - Basic earnings per share decreased to ¥0.61, down 93.18% from ¥8.95 in the previous year[29]. - The gross margin for the first half of 2022 was reported at 35%, a slight decrease from 37% in the previous year[20]. - Future guidance estimates revenue growth of 10-15% for the second half of 2022, driven by increased demand in the healthcare sector[20]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 20% increase in market share by the end of 2023[28]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[28]. - The company aims to strengthen its leadership position in the disposable glove industry and become a highly competitive player in the global personal protective equipment market[43]. - The company is expanding its product portfolio to include various personal protective equipment, such as masks and isolation gowns, through both in-house production and external procurement[63]. - The company plans to expand production capacity in Southeast Asia, including Vietnam, to leverage local resources and favorable policies[81]. Production and Capacity - The company has an annual production capacity of 75 billion disposable non-latex gloves, with 45 billion for nitrile gloves and 30 billion for PVC gloves[68]. - The company has established production bases in China and Vietnam, enhancing its capacity to meet global demand for personal protective equipment[43]. - The company’s production capacity for disposable gloves increased from 36 billion units in 2020 to 75 billion units by the end of 2021, with annualized capacity for nitrile gloves at 45 billion units and PVC gloves at 30 billion units[90]. - The company has invested over CNY 800 million in new production lines, with a single nitrile double-hand mold production line exceeding CNY 20 million[77]. Research and Development - The company is investing RMB 200 million in R&D for new medical technologies and products, aiming to launch three new products by the end of 2022[20]. - Research and development expenses totaled CNY 140,131,615, representing 3.75% of total revenue, with the company holding 93 registered patents as of the end of the reporting period[96]. - The company has accumulated over 10 years of production and R&D experience, holding 93 patents and 52 registered trademarks[71]. Risk Management - The management has identified key risks including regulatory changes and supply chain disruptions, with strategies in place to mitigate these risks[5]. - The company faces risks from raw material price fluctuations, which significantly impact production costs, particularly for PVC powder and nitrile latex[148]. - The company is implementing measures to manage exchange rate risks, including using forward foreign exchange contracts[149]. - The company is monitoring environmental regulations and may incur higher costs for pollution control measures[155]. Environmental and Social Responsibility - The company has implemented a comprehensive hazardous waste management system, ensuring all hazardous waste is collected, stored, and disposed of by qualified vendors, with regular tracking of disposal processes[176]. - The company has established an emergency response plan for environmental incidents, including a dedicated emergency response team and regular drills to ensure preparedness[178]. - The company donated 500,000 RMB to the Huai Bei Charity Association in May to support public welfare activities[186]. - During the COVID-19 pandemic, the company donated 10,000 sets of disposable virus sampling tubes and 625,000 medical N95 masks to frontline medical staff in Shanghai[188]. - The company actively engages in social responsibility initiatives, collaborating with local Red Cross and public welfare foundations[186]. Corporate Governance - The company has implemented four rounds of restricted stock incentive plans, granting incentives to over 1,400 individuals[85]. - The company held its first extraordinary shareholders' meeting on March 14, 2022, with a participation rate of 37.88%[162]. - The board of directors is responsible for proposing the cash dividend plan, which must be approved by a majority vote and include independent directors' opinions[198].

Financial Performance - The total revenue for 2021 was significantly impacted by market demand and national policies, with specific figures detailed in the financial report[6]. - The company's operating revenue for 2021 was ¥16,240,093,676, representing a 17.37% increase compared to ¥13,836,714,548 in 2020[29]. - The net profit attributable to shareholders for 2021 was ¥7,430,075,719, a 6.04% increase from ¥7,007,048,194 in 2020[29]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥7,385,676,483, up 5.42% from ¥7,005,746,722 in 2020[29]. - The total assets at the end of 2021 reached ¥20,624,644,774, a 59.45% increase from ¥12,934,808,129 at the end of 2020[29]. - The net assets attributable to shareholders at the end of 2021 were ¥15,871,195,748, reflecting a 69.86% increase from ¥9,343,841,318 at the end of 2020[29]. - The basic earnings per share for 2021 was ¥13.60, a decrease of 7.17% from ¥14.65 in 2020[29]. - The diluted earnings per share for 2021 was ¥13.20, down 2.73% from ¥13.57 in 2020[29]. - The company reported a net cash flow from operating activities of ¥8,680,078,255, a slight increase of 1.04% from ¥8,590,492,245 in 2020[29]. - The company's cash flow from operating activities reached CNY 8,680,078,255, up 1.04% year-on-year[89]. - The total assets at the end of the reporting period amounted to CNY 20,624,644,774, an increase of 59.45% from the previous year[89]. - The net assets attributable to shareholders grew by 69.86% to CNY 15,871,195,748[89]. - The company reported a decrease in net increase in cash and cash equivalents by 98.28% to ¥74,801,180, mainly due to reduced cash flow from investment and financing activities[129]. Market Strategy and Expansion - The company plans to expand its market presence and invest in new product development, although specific financial projections are subject to market uncertainties[6]. - The management team discussed potential mergers and acquisitions as part of the growth strategy, although specific targets were not disclosed[6]. - The company is adjusting its operational strategies in response to the market's transition from high demand during the pandemic to a more stable demand environment[45]. - The company aims to strengthen its leadership position in the disposable glove industry and become the most competitive player in the global personal protective equipment market[48]. - The company plans to expand production facilities in Southeast Asia, including Vietnam, to leverage local resources and favorable policies[81]. - The company plans to enhance its market competitiveness through the establishment of new subsidiaries in various regions, including Hainan and Japan[169]. - The company is considering potential mergers and acquisitions as part of its strategic initiatives to drive growth and innovation[197][200]. Product Development and Innovation - The company is focused on enhancing its research and development capabilities to drive innovation in medical technology[6]. - The company continuously expands its product portfolio to meet customer needs, including disposable PE gloves, masks, and hand sanitizers, which are essential for personal protection[64]. - The company successfully developed a dual-color nitrile glove with enhanced wear resistance, broadening its product range[117]. - A new high-elasticity PVC glove was launched, improving product quality and market competitiveness[120]. - The company is currently developing an anti-aging nitrile glove, which is in the testing phase, aimed at enhancing product stability[120]. - The introduction of a nitrile glove automatic packaging machine is underway, aimed at increasing automation and market competitiveness[120]. - The company intends to expand its product range, including the development of new materials and personal protective equipment, to meet changing customer demands and increase customer loyalty[186]. Research and Development - The company's R&D expenses totaled RMB 365,224,909, with a R&D expense ratio of 2.25%[96]. - The company employed 1,149 R&D personnel, making up 12.61% of the total workforce[96]. - Research and development expenses increased by 24.52% to ¥365,224,909 compared to the previous year[116]. - The number of R&D personnel increased to 1,149 in 2021, a growth of 60.92% compared to 714 in 2020, representing 12.61% of total employees[123]. - R&D investment amounted to ¥365,224,909 in 2021, up 24.52% from ¥293,301,423 in 2020, accounting for 2.25% of operating revenue[123]. Supply Chain and Production - The company has developed a comprehensive supply chain that integrates raw materials, production, and logistics, ensuring continuous growth[79]. - The company has established strict quality control systems for its personal protective equipment suppliers to ensure product quality[65]. - The company has accumulated sufficient capital for further capacity expansion, with significant investments in new production lines, including over 8 million RMB for PVC double-hand molds and over 20 million RMB for nitrile double-hand molds[78]. - The company has an annual production capacity of 75 billion disposable non-latex gloves, with 45 billion for nitrile gloves and 30 billion for PVC gloves[72]. - The company expanded its disposable glove production capacity from 36 billion units in 2020 to 75 billion units by the end of 2021[90]. - The company recognizes the need for compliance with various regulatory requirements across different jurisdictions, which poses a barrier to new entrants in the market[178]. - The company emphasizes the importance of supply chain management, as raw material costs constitute a major part of production expenses[175]. Investor Relations and Communication - The company conducted multiple investor meetings, including in-person and online sessions, throughout 2021, with a focus on engaging both institutional and individual investors[197][200]. - Key discussions during these meetings included insights into the company's performance and strategic direction, as detailed in the investor relations activity records[197][200]. - The company held a significant online conference call on July 13, 2021, to discuss its financial results and future outlook with institutional investors[197]. - On August 31, 2021, another online conference call was conducted, emphasizing the company's ongoing strategies and market positioning[200]. - The company has been actively expanding its investor communication efforts, with multiple sessions scheduled to enhance transparency and engagement with stakeholders[197][200]. - The focus of these discussions has been on performance summaries, user data, and future guidance, reflecting the company's commitment to providing detailed insights to investors[197][200]. Risks and Challenges - The company emphasizes the importance of risk awareness among investors regarding future plans and market conditions[6]. - The company faces risks from fluctuating raw material prices, which could impact profit margins if costs cannot be passed on to customers[193]. - The company is exposed to exchange rate risks, as over 90% of its revenue comes from exports, and a strengthening RMB could reduce profit margins[194]. - The company is concerned about potential delays in the construction of production bases due to market changes and regulatory approvals, which could affect future sales[195]. - The company is subject to increased environmental protection costs as regulations on pollution control become stricter[196].

Financial Performance - Revenue for Q1 2022 was CNY 2,287,865,174, a decrease of 66.03% compared to CNY 6,734,661,831 in the same period last year[3] - Net profit attributable to shareholders was CNY 83,493,070, down 97.77% from CNY 3,735,722,692 year-on-year[3] - Basic earnings per share decreased to CNY 0.15, a decline of 97.93% from CNY 7.24 in the previous year[3] - Total operating revenue for the current period is 2,287,865,174.00, a decrease of approximately 66.0% compared to the previous period's 6,734,661,831.00[30] - The net profit for the current period is 79,471,291.00, compared to 3,734,237,292.00 in the previous period, indicating a significant decrease[33] - The total profit for the current period is 104,876,218.00, down from 4,422,209,795.00 in the previous period[33] - The operating profit for the current period is 108,517,738.00, compared to 4,424,020,628.00 in the previous period[33] - The total comprehensive income for the current period is 76,357,401.00, compared to 3,739,918,415.00 in the previous period[36] - The company reported a decrease in sales revenue from 5,396,786,425.00 in the previous period to 1,977,957,759.00 in the current period[37] Cash Flow and Assets - Net cash flow from operating activities was CNY 416,703,728, down 86.45% from CNY 3,075,354,570 in the same period last year[3] - The company's cash and cash equivalents at the end of March 2022 amount to ¥4,819,885,228, down from ¥5,002,855,287 at the beginning of the year[20] - The cash flow from operating activities for the current period is 416,703,728.00, a decrease from 3,075,354,570.00 in the previous period[40] - The cash and cash equivalents at the end of the period are 4,796,143,801.00, down from 6,934,091,947.00 in the previous period[43] - The net cash flow from investing activities is -878,548,703.00, compared to -1,135,811,036.00 in the previous period[40] - The net cash flow from financing activities is 304,588,408.00, an increase from 52,681,053.00 in the previous period[40] - Total assets at the end of Q1 2022 were CNY 20,557,983,278, a slight decrease of 0.32% from CNY 20,624,644,774 at the end of the previous year[3] - The company's total assets amount to 20,557,983,278.00, slightly down from 20,624,644,774.00 in the previous period[29] - The company's cash and cash equivalents have decreased, with total current assets at 10,437,677,802.00 compared to 10,762,722,389.00 previously, a decline of about 3.0%[29] Liabilities and Shareholder Information - The company reported a significant increase in short-term borrowings, which rose by 519.04% to CNY 312,517,672[6] - The company’s long-term borrowings have increased to 243,714,318.00 from 198,500,000.00, reflecting a growth of approximately 22.8%[26] - Total liabilities are reported at 4,352,063,434.00, a decrease from 4,501,196,482.00 in the previous period[29] - Total number of common shareholders at the end of the reporting period is 97,156, with the largest shareholder, Liu Fangyi, holding 35.06% of shares, equating to 192,684,673 shares[10] - Liu Fangyi holds 48,171,168 unrestricted shares, while Hong Kong Central Clearing Limited holds 11,722,848 unrestricted shares[14] - The total equity attributable to shareholders of the parent company is 15,957,689,079.00, up from 15,871,195,748.00, indicating a growth of about 0.5%[29] Research and Development - Research and development expenses decreased by 32.44% to CNY 69,568,207 compared to CNY 102,972,246 in the same period last year[6] - Research and development expenses for the current period amount to 69,568,207.00, a decrease of approximately 32.4% from 102,972,246.00 in the previous period[30] Other Income and Investments - Other income increased by 389.18% to CNY 18,853,836, primarily due to government subsidies received[9] - The company has a significant focus on expanding its investment channels and diversifying investment risks[19] - The company invested ¥30 million in Wuxi Shangxianhu Boshang Investment Partnership to expand investment channels[19] - The company is actively pursuing overseas strategic mergers and acquisitions through investments in partnerships[19] - A total of 433,930 restricted shares were repurchased and canceled by the company in February 2022[19] - The subsidiary Anhui Kaize New Materials Co., Ltd. has entered trial production for a project with an annual capacity of 500,000 tons of carboxylated nitrile latex[19]

证券代码：300677 证券简称：英科医疗 公告编号：2021-134 英科医疗科技股份有限公司 关于参加山东辖区上市公司 2021 年度 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，英科医疗科技股份有限公司 （以下简称"公司"）将参加"山东辖区上市公司 2021 年度投资者网上 集体接待日"活动，现将有关事项公告如下：本次集体接待日活动将 通过深圳市全景网络有限公司提供的互联网平台举行，投资者可登录 "全景•路演天下"（http://rs.p5w.net）参与公司本次投资者集体接待日 活动，活动时间为 2021 年 11 月 16 日（星期二）14:00-16:00。 届时公司董事会秘书李斌先生、证券事务代表宋且未女士、刘文 静女士，将通过网络在线交流形式与投资者就公司治理、经营状况、 风险防控等投资者关注的问题进行沟通。欢迎广大投资者积极参与！ 特此公告。 英科医疗科技股份有限公司 董 事 会 2021年11月12日 ...